Zhengye Biotechnology (ZYBT) Competitors $6.05 +0.13 (+2.20%) As of 07/3/2025 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock ZYBT vs. VERA, JANX, EVO, OCUL, MESO, TVTX, BGM, GPCR, CVAC, and CALTShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Vera Therapeutics (VERA), Janux Therapeutics (JANX), Evotec (EVO), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Its Competitors Vera Therapeutics Janux Therapeutics Evotec Ocular Therapeutix Mesoblast Travere Therapeutics BGM Group Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Vera Therapeutics (NASDAQ:VERA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Do insiders and institutionals hold more shares of VERA or ZYBT? 99.2% of Vera Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation & earnings, VERA or ZYBT? Zhengye Biotechnology has higher revenue and earnings than Vera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$152.15M-$3.00-7.92Zhengye Biotechnology$25.53M11.18N/AN/AN/A Is VERA or ZYBT more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -40.59% -34.54% Zhengye Biotechnology N/A N/A N/A Do analysts rate VERA or ZYBT? Vera Therapeutics currently has a consensus target price of $65.00, suggesting a potential upside of 173.74%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor VERA or ZYBT? In the previous week, Zhengye Biotechnology had 5 more articles in the media than Vera Therapeutics. MarketBeat recorded 5 mentions for Zhengye Biotechnology and 0 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.67 beat Zhengye Biotechnology's score of -0.03 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Vera Therapeutics Positive Zhengye Biotechnology Neutral SummaryVera Therapeutics beats Zhengye Biotechnology on 7 of the 11 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$285.36M$2.89B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E RatioN/A21.7127.6620.25Price / Sales11.18281.81415.41118.18Price / CashN/A42.7336.8958.07Price / BookN/A7.518.035.67Net IncomeN/A-$55.14M$3.18B$249.21M7 Day Performance-8.47%4.61%2.93%3.27%1 Month Performance-3.82%4.72%3.75%5.55%1 Year PerformanceN/A5.92%35.20%21.08% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$6.05+2.2%N/AN/A$285.36M$25.53M0.00278News CoverageLockup ExpirationVERAVera Therapeutics3.3774 of 5 stars$22.58+4.3%$65.00+187.9%-31.9%$1.38BN/A-7.5340High Trading VolumeJANXJanux Therapeutics1.4517 of 5 stars$23.35+2.1%$95.25+307.9%-36.3%$1.35B$10.59M-17.1730EVOEvotec1.7188 of 5 stars$4.08+7.1%$5.93+45.4%-18.5%$1.35B$862.40M0.004,827News CoverageGap UpOCULOcular Therapeutix3.9657 of 5 stars$9.09+8.6%$17.33+90.7%+39.9%$1.33B$63.72M-7.90230Positive NewsHigh Trading VolumeMESOMesoblast2.3792 of 5 stars$10.45+2.9%$18.00+72.2%+58.6%$1.30B$5.90M0.0080Positive NewsTVTXTravere Therapeutics3.1787 of 5 stars$15.24+5.2%$32.14+110.9%+88.9%$1.29B$233.18M-5.42460Analyst ForecastAnalyst RevisionBGMBGM GroupN/A$12.91-1.6%N/AN/A$1.28B$25.10M0.00298High Trading VolumeGPCRStructure Therapeutics2.9243 of 5 stars$22.38+1.3%$76.17+240.3%-44.9%$1.27BN/A-25.72136Positive NewsCVACCureVac4.6385 of 5 stars$5.36-0.6%$9.00+67.9%+72.9%$1.21B$579.18M5.83880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies VERA Alternatives JANX Alternatives EVO Alternatives OCUL Alternatives MESO Alternatives TVTX Alternatives BGM Alternatives GPCR Alternatives CVAC Alternatives CALT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
